Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2006
11/23/2006WO2006124626A2 Inhibition of the 44 kilodalton isoform of pim-1 kinase restores apoptosis induced by chemotherapeutic drugs in cancer cells
11/23/2006WO2006124375A2 Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
11/23/2006WO2006123827A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006WO2006123817A1 Method for delivering nucleic acid and device for delivering nucleic acid
11/23/2006WO2006123644A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF
11/23/2006WO2006123631A1 Rna-containing composition
11/23/2006WO2006123248A2 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
11/23/2006WO2006122971A2 Treatment of disease using an improved regulated expression system
11/23/2006WO2006096441A3 Reagents, methods and systems to suppress phospholamban expression
11/23/2006WO2006078640A3 Alterations utilizing nanoparticles
11/23/2006WO2006063067A3 Novel tnf receptor regulatory domain
11/23/2006WO2006060051A3 Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis
11/23/2006WO2006047250A3 Use of apoptosis inhibiting compounds in degenerative neurological disorders
11/23/2006WO2006036465A3 Compositions and methods for treating cystic fibrosis
11/23/2006WO2006024880A3 Methods and compositions to inhibit p2x7 receptor expression
11/23/2006WO2006016097A3 Vector comprising polymer modified sirna liposomes
11/23/2006WO2005118825A3 Chimeric adenoviruses for use in cancer treatment
11/23/2006WO2005074995A3 Combined use of prame inhibitors and hdac inhibitors
11/23/2006US20060265773 Methods for producing transgenic animals with modified disease resistance
11/23/2006US20060265765 Oncogene HOXB13 and its siRNAs
11/23/2006US20060265763 Dyrks as modifiersof the apc and axin pathways and methods of use
11/23/2006US20060264615 Which induce proliferation of lymphocytes in presence of wild-type p35 polypeptide subunit of human interleukin-12; site directed mutagenesis
11/23/2006US20060264609 Use of heat shock proteins
11/23/2006US20060264396 Nucleic acid inducing RNA interference against syndecan gene expression; adminstering in vitro to inhibit cell growth
11/23/2006US20060264395 Modulation of apolipoprotein c-III expression
11/23/2006US20060264394 Livin-specific sirnas for the treatment of therapy-resistant tumors
11/23/2006US20060264393 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases
11/23/2006US20060264392 Modulators of angiogenesis
11/23/2006US20060264391 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
11/23/2006US20060264371 Treatment
11/23/2006US20060264366 Identifying an agent that inhibits binding of mammalian Mcl-1 with a human or mouse Mule polypeptide having a Mule BH3 domain by contacting the mixture with a candidate agent and detecting an agent-biased binding that is different from the reference binding, indicating that the agent is an inhibitor
11/23/2006US20060264363 Inhibition of nerve cell death by inhibiting degradation of shc3, atf6 or crebl1 by htra2 and method of ameliorating neurodegenerative diseases
11/23/2006US20060264359 inducing eosinophil apoptosis; Pin1 inhibitor is juglone
11/23/2006US20060264357 Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
11/23/2006US20060263883 Recombinant herpes viruses for preparing recombinant adeno-associated viruses
11/23/2006US20060263882 Multi-cistronic vectors for gene transfer protocols
11/23/2006US20060263852 Asp2
11/23/2006US20060263828 Arrestin chimera comprising naturally occurring beta-arrestin-2 and naturally occurring ubiquitin moiety, where arrestin chimera has increased affinity for GPCR, and where increased affinity means that arrestin chimera remains associated with and traffics with GPCR into endosomes
11/23/2006US20060263776 Serine protease
11/23/2006US20060263435 nucleic acid such as siRNAs; carrier includes a cyclodextrin polymer; treatment of cell proliferative disorders, such as cancer or pathogen infections
11/23/2006US20060263422 Pharmaceutical composition containing decoy and use of the same
11/23/2006US20060263389 Methods and compositions to enhance immune responses via recall antigens
11/23/2006US20060263381 Peptide epitopes common to antigens of the same multigene family
11/23/2006US20060263359 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
11/23/2006US20060263345 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
11/23/2006US20060263343 Molecular dissection of cellular responses to alloantigen or autoantigen in graft rejection and autoimmune disease
11/23/2006US20060263342 Peptides derived from a protein encoded by a polynucleotide overexpressed in human colon cancer cells; bladder, prostate and breast cancers; antimetastasis agents; diagnosis
11/23/2006US20060263334 Therapeutic and diagnostic cloned MHC-unrestricted receptor specific for the MUC1 tumor associated antigen
11/23/2006US20060263333 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
11/23/2006DE102005023993A1 Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge Non-viral vector system for transporting nucleic acid into the lungs
11/23/2006DE102005023170A1 Optimierte Formulierung für mRNA Optimized formulation for mRNA
11/23/2006DE102004054731A1 New pharmaceutical composition comprising an oligonucleotide that is adapted to target nucleic acids encoding CD40, useful for preventing or treating an inflammatory, immune or autoimmune disorder
11/23/2006CA2614608A1 Anti-tumoral compositions and methods
11/23/2006CA2612538A1 A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
11/23/2006CA2609814A1 Method for amelioration of disease condition induced by mood disorder
11/23/2006CA2609102A1 Int6 protein involved in hypoxia stress induction and use thereof
11/23/2006CA2608764A1 Treatment of disease using an improved regulated expression system
11/23/2006CA2607291A1 Compositions and methods for modulating immune responses
11/23/2006CA2604452A1 Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
11/23/2006CA2597511A1 Hivcon: an hiv immunogen and uses thereof
11/22/2006EP1724354A2 Circular DNA molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy
11/22/2006EP1724353A2 Methods of forming protein-linked lipidic microparticles
11/22/2006EP1724351A2 Human Kallikrein-like genes
11/22/2006EP1724350A1 Method and compositions for the diagnosis and treatment of cancer
11/22/2006EP1724339A1 Gene regulation therapy involving ferritin
11/22/2006EP1723970A1 Medicinal composition containing cxcr3 inhibitor
11/22/2006EP1723950A2 Method of treating dopaminergic gaba-nergic disorders
11/22/2006EP1723417A1 C20orf23 as modifier of the igfr pathway and methods of use
11/22/2006EP1723415A1 Pdes as modifiers of the igfr pathway and methods of use
11/22/2006EP1723238A1 Modified oncolytic viruses
11/22/2006EP1723177A2 Rab9a, rab11a, and modulators thereof related to infectious disease
11/22/2006EP1723166A2 Materials and methods relating to the treatment of glioblastomas
11/22/2006EP1723162A2 Anti-microrna oligonucleotide molecules
11/22/2006EP1722823A2 Pharmaceutical composition
11/22/2006EP1722760A2 Delivery of genes encoding short hairpin rna using receptor-specific nanocontainers
11/22/2006EP1244651B1 Diamidine compounds as dna minor groove binders
11/22/2006EP1214098B1 Capsid-modified recombinant adenovirus and methods of use
11/22/2006EP1163522B1 Method for detecting msrv-1 induced superantigen activity in a biological sample
11/22/2006EP1071774B1 Isolated sh3 genes associated with myeloproliferative disorders and leukemia, and uses thereof
11/22/2006EP1053309B1 Compositions and methods for wound healing
11/22/2006EP1000158B1 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
11/22/2006EP0939821B1 G-beta-gamma regulated phosphatidylinositol-3' kinase
11/22/2006EP0935415B1 In vitro methods for delivering nucleic acids into a cell
11/22/2006EP0825996B1 Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use
11/22/2006CN1867362A Cancer gene therapeutic drug
11/22/2006CN1867361A Cancer gene therapeutic drug
11/22/2006CN1865449A 病毒株 Strains
11/22/2006CN1865442A SiRNA sequence aimed at hepatitis B virus gene and its uses
11/22/2006CN1865284A Receptor of the edb-fibronectin domains
11/21/2006US7138569 Nucleic acids encoding pseudomonas hop proteins and use thereof
11/21/2006US7138517 Sugar modified oligonucleotides
11/21/2006US7138512 Gene SHINC-2 and diagnostic and therapeutic uses thereof
11/21/2006US7138511 Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
11/21/2006US7138508 Inhibitor protein of the wnt signal pathway
11/21/2006US7138492 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
11/21/2006US7138383 That retains the high RNA binding affinity of the parent oligonucleotide N3' --> P5' phosphoramidates and exhibits a much higher acid stability; inhibiting human telomerase enzyme activity
11/21/2006US7138382 Compositions and methods for drug delivery using pH sensitive molecules
11/21/2006US7138381 Compositions containing nucleic acids and ligands for therapeutic treatment
11/21/2006US7138380 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
11/21/2006US7138379 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons